Open-label phase IV clinical trial to evaluate the effect of nasal testosterone gel on reproductive hormones and semen parameters in hypogonadal men

Low testosterone (low T) affects around 12% of men under age of 40 and prescriptions for testosterone replacement therapy (TRT) to men of reproductive age are increasing. Unfortunately, most commonly prescribed TRT as gels, patches, injections and pellets are long-acting and can cause azoospermia in up to 65% of men. Therefore, it is imperative to identify an option for increasing T while minimizing effects on semen parameters. Natesto ® (125 uL/nostril, 11.0 mg testosterone/dose, three times a day (TID)) is a short-acting, FDA approved nasal TRT available since 2015.
Source: Fertility and Sterility - Category: Reproduction Medicine Authors: Tags: Late-Breaking 1 Source Type: research